地塞米松对食管恶性肿瘤相关性疲乏的疗效研究  

Efficacy of dexamethasone for improving cancer-related fatigue of esophageal cancer patients

作　　者：张寒[1] 覃川[2] 邓超[1] 张力[1] 李刚[1] 

机构地区：[1]重庆三峡中心医院消化肿瘤科,重庆404000 [2]重庆三峡中心医院普外一科,重庆404000

出　　处：《世界临床药物》2016年第1期46-49,共4页World Clinical Drug

摘　　要：目的评价地塞米松对食管恶性肿瘤疲乏及其相关症状的临床疗效。方法纳入食管恶性肿瘤患者50例,随机分为治疗组和对照组,分别静脉给予地塞米松及安慰剂,治疗14 d。纳入患者在入组24 h以及疗程结束后完成MDASI量表填写,以治疗前后患者MDASI评分评估疗效。结果治疗后所有纳入患者疲乏症状均有所减轻,且与对照组比较,治疗组患者疲乏评分降低更为显著,组间比较差异具有统计学意义(P<0.05)。此外,两组患者治疗后疼痛、食欲减退、气促、恶心和呕吐等症状也有所减轻,减轻幅度组间差异也具有统计学意义(P<0.05)。结论地塞米松能够在短时间内有效改善肿瘤相关性疲乏,有助于提高晚期肿瘤患者的生活质量。Objective To evaluate the efficacy of dexamethasone for improving cancer-related fatigue of esophageal cancer patients. Methods A total of 50 patients with esophageal cancer were randomly divided dexamethasone therapeutic group and placebo group for 14 day performance. The efficacy was evaluated by using MDASI scale, Results Cancer-related fatigue of all the patients enrolled onto this study got alleviated. And the improvement of fatigue score on MDASI scale in dexamethasone group was significant better than in placebo group （P〈0.05）. The improvements of pain, appetite, shortness of breath, nausea and vomiting in dexamethasone group were also notably better （P〈0.05）. Conclusion Dexamethasone is effective for improving cancer-related fatigue in a short time.

关 键 词：食管恶性肿瘤 肿瘤相关性疲乏(CRF) 地塞米松 

分 类 号：R735.1[医药卫生—肿瘤] R977.11[医药卫生—临床医学]